JP2004285076A5 - - Google Patents

Download PDF

Info

Publication number
JP2004285076A5
JP2004285076A5 JP2004155357A JP2004155357A JP2004285076A5 JP 2004285076 A5 JP2004285076 A5 JP 2004285076A5 JP 2004155357 A JP2004155357 A JP 2004155357A JP 2004155357 A JP2004155357 A JP 2004155357A JP 2004285076 A5 JP2004285076 A5 JP 2004285076A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004155357A
Other languages
Japanese (ja)
Other versions
JP2004285076A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2004285076A publication Critical patent/JP2004285076A/ja
Publication of JP2004285076A5 publication Critical patent/JP2004285076A5/ja
Withdrawn legal-status Critical Current

Links

JP2004155357A 1992-06-09 2004-05-25 M−csfの結晶化 Withdrawn JP2004285076A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89651292A 1992-06-09 1992-06-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP6501713A Division JPH08507916A (ja) 1992-06-09 1993-06-09 M−csfの結晶化

Publications (2)

Publication Number Publication Date
JP2004285076A JP2004285076A (ja) 2004-10-14
JP2004285076A5 true JP2004285076A5 (show.php) 2005-08-11

Family

ID=25406334

Family Applications (2)

Application Number Title Priority Date Filing Date
JP6501713A Withdrawn JPH08507916A (ja) 1992-06-09 1993-06-09 M−csfの結晶化
JP2004155357A Withdrawn JP2004285076A (ja) 1992-06-09 2004-05-25 M−csfの結晶化

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP6501713A Withdrawn JPH08507916A (ja) 1992-06-09 1993-06-09 M−csfの結晶化

Country Status (7)

Country Link
US (2) US5866114A (show.php)
EP (2) EP0668914B1 (show.php)
JP (2) JPH08507916A (show.php)
AT (1) ATE195553T1 (show.php)
CA (1) CA2137793C (show.php)
DE (1) DE69329247T2 (show.php)
WO (1) WO1993025687A1 (show.php)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
WO1997033613A1 (en) * 1996-03-14 1997-09-18 Board Of Trustees Of The University Of Illinois Parasite-derived anti-inflammatory immunomodulatory protein
AU1759501A (en) * 1999-11-08 2001-06-06 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Method of treating a viral infection using antagonists of macrophage colony stimulating factor
MXPA03007042A (es) 2001-02-09 2004-05-24 Genentech Inc Cristalizacion de igf-1.
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
WO2003006501A2 (en) 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
US7563595B2 (en) * 2002-11-08 2009-07-21 University Of South Florida Nucleic acids encoding functional splice variants of the α7 nicotinic acetylcholine receptor subunit and methods for producing the encoded proteins
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US20050124008A1 (en) * 2003-12-05 2005-06-09 Kauvar Lawrence M. Homogeneous competition assays
JP2007524671A (ja) * 2004-01-21 2007-08-30 カイロン コーポレイション M−csfムテインおよびその使用
US20060094081A1 (en) * 2004-10-22 2006-05-04 Carsten Schubert Crystal structure of the c-fms kinase domain: applications and use of heterologous substitutions of kinase insert domains for crystallization
EP1888119B1 (en) 2005-06-01 2011-03-09 Maxygen, Inc. Pegylated g-csf polypeptides and methods of producing same
KR100970770B1 (ko) 2008-02-12 2010-07-16 한국기초과학지원연구원 결정성 재조합 단백질 휴먼 에스피오티 및 이의 결정화방법
US8080246B2 (en) * 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
US8183207B2 (en) * 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
TWI504598B (zh) * 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
HUE026201T2 (en) * 2009-12-10 2016-05-30 Hoffmann La Roche Antibodies binding to human CSF1R extracellular domain 4 and their use
EP2542587A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
WO2011131407A1 (en) 2010-03-05 2011-10-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
SG185035A1 (en) 2010-05-04 2012-11-29 Five Prime Therapeutics Inc Antibodies that bind csf1r
US20140378537A1 (en) 2011-09-09 2014-12-25 Genentech, Inc. Treatment of th17 mediated inflammatory diseases
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2014036357A1 (en) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2016069727A1 (en) 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2016106180A1 (en) 2014-12-22 2016-06-30 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
PL3283527T3 (pl) 2015-04-13 2021-06-14 Five Prime Therapeutics, Inc. Leczenie skojarzone nowotworów
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療
CN106843149A (zh) * 2017-03-28 2017-06-13 吴小江 一种机械零固件产品加工系统
EP3681535A1 (en) 2017-09-13 2020-07-22 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS62106000A (ja) * 1985-10-30 1987-05-16 Fujitsu Ltd 生体高分子結晶自動作製装置
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
WO1988003173A2 (en) * 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
ATE111921T1 (de) * 1988-06-03 1994-10-15 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung.
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
EP0506866B1 (en) * 1989-12-21 1993-10-20 Novo Nordisk A/S Method for crystallization of enzymes
WO1992021029A1 (en) * 1991-05-10 1992-11-26 Genentech, Inc. Selecting ligand agonists and antagonists

Similar Documents

Publication Publication Date Title
BE2024C508I2 (show.php)
BE2023C542I2 (show.php)
BE2022C549I2 (show.php)
BE2021C001I2 (show.php)
BE2020C513I2 (show.php)
BE2020C517I2 (show.php)
BE2019C540I2 (show.php)
BE2019C523I2 (show.php)
BE2019C548I2 (show.php)
BE2019C506I2 (show.php)
BE2018C045I2 (show.php)
BE2020C525I2 (show.php)
BE2017C063I2 (show.php)
BE2017C027I2 (show.php)
BE2017C023I2 (show.php)
BE2017C002I2 (show.php)
BE2016C067I2 (show.php)
BE2016C014I2 (show.php)
BE2015C041I2 (show.php)
BE2015C038I2 (show.php)
BE2015C066I2 (show.php)
BE2012C025I2 (show.php)
JP2005292347A5 (show.php)
BE2015C065I2 (show.php)
BE2019C535I2 (show.php)